Review





Similar Products

99
ATCC atcc modification
Atcc Modification, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/atcc modification/product/ATCC
Average 99 stars, based on 1 article reviews
atcc modification - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier

99
Thermo Fisher dna modification
Dna Modification, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dna modification/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
dna modification - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier

95
MedChemExpress minor modifications
Minor Modifications, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/minor modifications/product/MedChemExpress
Average 95 stars, based on 1 article reviews
minor modifications - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier

86
Hermetia Baruth acids genetic modification ilp2 hermetia illucens
Acids Genetic Modification Ilp2 Hermetia Illucens, supplied by Hermetia Baruth, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/acids genetic modification ilp2 hermetia illucens/product/Hermetia Baruth
Average 86 stars, based on 1 article reviews
acids genetic modification ilp2 hermetia illucens - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Synthego Inc phosphorothioate modifications
Phosphorothioate Modifications, supplied by Synthego Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phosphorothioate modifications/product/Synthego Inc
Average 86 stars, based on 1 article reviews
phosphorothioate modifications - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Biomark Inc m6a rna methylation modification
M6a Rna Methylation Modification, supplied by Biomark Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/m6a rna methylation modification/product/Biomark Inc
Average 86 stars, based on 1 article reviews
m6a rna methylation modification - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Isis Pharmaceuticals 2 methoxyethyl moe modification
2 Methoxyethyl Moe Modification, supplied by Isis Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/2 methoxyethyl moe modification/product/Isis Pharmaceuticals
Average 86 stars, based on 1 article reviews
2 methoxyethyl moe modification - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Boston Scientific Corporation plaque modification
Plaque Modification, supplied by Boston Scientific Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plaque modification/product/Boston Scientific Corporation
Average 86 stars, based on 1 article reviews
plaque modification - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

94
TargetMol targetmol epigenetic inhibitors
High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC <t>epigenetic</t> compounds, FDA-approved oncology drugs, and TargetMol epigenetic <t>inhibitors.</t> (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.
Targetmol Epigenetic Inhibitors, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/targetmol epigenetic inhibitors/product/TargetMol
Average 94 stars, based on 1 article reviews
targetmol epigenetic inhibitors - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

86
Adipogen polyglutamylation modification
A. Amino acid quantification in colon tissues of WT mice and xCT KO mice on days 0, 3, and 5 of 3% DSS treatment (n=3-4, per group). B. Protein <t>polyglutamylation</t> in colon epithelial tissues of WT mice and xCT KO mice with and without 3% DSS treatment on day 7. Tubulin was detected as a loading control. Band intensities were quantified using the Image J. C. Protein polyglutamylation in colon biopsy specimens of UC patients. The biopsy specimens during the active phase (MES3) and remission phase (MES1) were obtained. Tubulin was detected as a loading control. Band intensities were quantified using the Image J. Data represent means ± standard deviation. A was analyzed by one-way ANOVA. B and C were analyzed by non-parametric Mann-Whitney test. **p<0.01, ***p<0.001, ****p<0.0001; ns, not significant.
Polyglutamylation Modification, supplied by Adipogen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyglutamylation modification/product/Adipogen
Average 86 stars, based on 1 article reviews
polyglutamylation modification - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

Journal: bioRxiv

Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer

doi: 10.64898/2026.04.16.719008

Figure Lengend Snippet: High-throughput drug screen and MEK inhibitor sensitivity in MRTX1719-resistant NSCLC cells. (A) Composition of the compound library used for drug screen, including SGC epigenetic compounds, FDA-approved oncology drugs, and TargetMol epigenetic inhibitors. (B) IC50 values of MRTX1719 and anisomycin in DMSO and MRTXR cells. Anisomycin was included as a nonselective control in the drug screen. (C) Dose-response curves of DMSO and MRTXR cells treated with the MEK inhibitor selumetinib. Data are presented as mean ± SD. (D) Synergy heatmaps of MRTX1719 and selumetinib in DMSO and MRTXR cells. Synergy mean scores were calculated using the Bliss model with the SynergyFinder+ tool.

Article Snippet: The screening library comprised 619 compounds, including SGC epigenetic compounds, TargetMol epigenetic inhibitors, and FDA-approved oncology drugs ( ).

Techniques: High Throughput Screening Assay, Drug discovery, Control

A. Amino acid quantification in colon tissues of WT mice and xCT KO mice on days 0, 3, and 5 of 3% DSS treatment (n=3-4, per group). B. Protein polyglutamylation in colon epithelial tissues of WT mice and xCT KO mice with and without 3% DSS treatment on day 7. Tubulin was detected as a loading control. Band intensities were quantified using the Image J. C. Protein polyglutamylation in colon biopsy specimens of UC patients. The biopsy specimens during the active phase (MES3) and remission phase (MES1) were obtained. Tubulin was detected as a loading control. Band intensities were quantified using the Image J. Data represent means ± standard deviation. A was analyzed by one-way ANOVA. B and C were analyzed by non-parametric Mann-Whitney test. **p<0.01, ***p<0.001, ****p<0.0001; ns, not significant.

Journal: bioRxiv

Article Title: Epithelial Glutamate Retention Protects against Colitis

doi: 10.64898/2026.04.18.718419

Figure Lengend Snippet: A. Amino acid quantification in colon tissues of WT mice and xCT KO mice on days 0, 3, and 5 of 3% DSS treatment (n=3-4, per group). B. Protein polyglutamylation in colon epithelial tissues of WT mice and xCT KO mice with and without 3% DSS treatment on day 7. Tubulin was detected as a loading control. Band intensities were quantified using the Image J. C. Protein polyglutamylation in colon biopsy specimens of UC patients. The biopsy specimens during the active phase (MES3) and remission phase (MES1) were obtained. Tubulin was detected as a loading control. Band intensities were quantified using the Image J. Data represent means ± standard deviation. A was analyzed by one-way ANOVA. B and C were analyzed by non-parametric Mann-Whitney test. **p<0.01, ***p<0.001, ****p<0.0001; ns, not significant.

Article Snippet: The antibodies used were as follows: anti polyglutamylation modification (Adipogen, AG-20B-0020B-C100) and anti-tubulin (Sigma, T9026).

Techniques: Control, Standard Deviation, MANN-WHITNEY

Scheme of MSO administration experiment in 3% DSS colitis. WT mice were divided into two groups, MSO group (10 mg/kg/day, n=8) and control group (equal volume of PBS, n=8), and administered with MSO or PBS, respectively, by intraperitoneal injection once daily from day 0 to day 6. B-E. Effects of MSO on DSS colitis were examined. Body weight changes ( B ), DAI score ( C ), and colon length measurement and macroscopic observation of colon tissues ( D ) are shown. Histological score and HE staining of colon tissues are shown with scale bars corresponding to 1 mm for lower magnification and 100 μm for higher magnification ( E ). Data are shown as mean□±□SD from three independent experiments. F. Protein polyglutamylation in colon tissues of WT mice treated with MSO or PBS together with 3% DSS on day 5. Tubulin was detected as a loading control. Band intensities were quantified using the Image J. Data represent means ± standard deviation. B and C were analyzed by two-way ANOVA. D-F were analyzed by two-sided Student’s t-test. **p<0.01, ****p<0.0001; ns, not significant.

Journal: bioRxiv

Article Title: Epithelial Glutamate Retention Protects against Colitis

doi: 10.64898/2026.04.18.718419

Figure Lengend Snippet: Scheme of MSO administration experiment in 3% DSS colitis. WT mice were divided into two groups, MSO group (10 mg/kg/day, n=8) and control group (equal volume of PBS, n=8), and administered with MSO or PBS, respectively, by intraperitoneal injection once daily from day 0 to day 6. B-E. Effects of MSO on DSS colitis were examined. Body weight changes ( B ), DAI score ( C ), and colon length measurement and macroscopic observation of colon tissues ( D ) are shown. Histological score and HE staining of colon tissues are shown with scale bars corresponding to 1 mm for lower magnification and 100 μm for higher magnification ( E ). Data are shown as mean□±□SD from three independent experiments. F. Protein polyglutamylation in colon tissues of WT mice treated with MSO or PBS together with 3% DSS on day 5. Tubulin was detected as a loading control. Band intensities were quantified using the Image J. Data represent means ± standard deviation. B and C were analyzed by two-way ANOVA. D-F were analyzed by two-sided Student’s t-test. **p<0.01, ****p<0.0001; ns, not significant.

Article Snippet: The antibodies used were as follows: anti polyglutamylation modification (Adipogen, AG-20B-0020B-C100) and anti-tubulin (Sigma, T9026).

Techniques: Control, Injection, Staining, Standard Deviation